Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 5/20 | 0.49 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 7/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 7/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | FABP2 | P12104 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.36 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bermoprofen SCHEMBL25434 | 1.00 | PTGS1 (0.49) | PTGS1ABCC4PTGS2OPRK1PDE4D | |
| SCHEMBL14434968 | 0.93 | PTGS1 (0.41) | PTGS1ABCC4PTGS2OPRK1PDE4D | |
| SCHEMBL13875314 | 0.89 | PTGS1 (0.38) | PTGS1ABCC4PTGS2OPRK1PDE4D | |
| Bermoprofen SCHEMBL11441448 | 0.88 | PTGS1 (0.39) | PTGS1ABCC4PTGS2OPRK1PDE4D | |
| SCHEMBL11339446 | 0.86 | PTGS2 (0.54) | PTGS1ABCC4PTGS2OPRK1PDE4D | |
| SCHEMBL13241522 | 0.86 | LMNA (0.37) | PTGS1ABCC4MEN1KMT2ALMNA | |
| SCHEMBL13220682 | 0.84 | KDM4E (0.35) | PTGS1ABCC4PTGS2OPRK1PDE4D | |
| SCHEMBL11576098 | 0.81 | KDM4E (0.45) | MEN1KMT2AHPGD | |
| SCHEMBL13777304 | 0.81 | KDM4E (0.39) | PTGS1ABCC4PTGS2OPRK1PDE4D | |
| SCHEMBL11344285 | 0.80 | PTGS1 (0.33) | PTGS1ABCC4PTGS2OPRK1PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4642771-A1 | AMINE DERIVATIVES OF DIHYDRODIBENZO[b,f]OXEPINES AND METHOD OF PREPARATION THEREOF | POLITECHNIKA WARSZAWSKA (PL) | 2025-11-05 | — | — | EP | disclosed |
| US-20250304667-A1 | COMPLEMENT COMPONENT C5 ANTIBODIES | ALLERGAN INC (US) | 2025-10-02 | — | — | US | disclosed |
| EP-3693381-B1 | LIGAND BINDING MOLECULES AND USES THEREOF | VEGENICS PTY LTD (AU) | 2025-09-03 | — | — | EP | disclosed |
| US-20250161402-A1 | THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF DRY EYE DISEASE | SCHEPENS EYE RES INST (US) | 2025-05-22 | — | — | US | disclosed |
| CN-119947704-A | Vapor deposition techniques for preparing pharmaceutical compositions | 南爱克萨股份公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-114716544-B | Complement component C5 antibodies | 阿勒根公司 | 2024-10-01 | — | — | CN | disclosed |
| US-20240301370-A1 | Ligand Binding Molecules and Uses Thereof | VEGENICS PTY LIMITED (AU) | 2024-09-12 | — | — | US | disclosed |
| US-20240279317-A1 | COMPLEMENT COMPONENT C5 ANTIBODIES | ALLERGAN INC (US) | 2024-08-22 | — | — | US | disclosed |
| WO-2024162861-A1 | AMINE DERIVATIVES OF DIHYDRODIBENZO[b,ƒ]OXEPINES AND METHOD OF PREPARATION THEREOF | POLITECHNIKA WARSZAWSKA (PL) | 2024-08-08 | — | — | WO | disclosed |
| US-20240189337-A1 | NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF | ASCLETIS BIOSCIENCE CO LTD (CN) | 2024-06-13 | — | — | US | disclosed |
| US-11866739-B2 | Ligand binding molecules and uses thereof | VEGENICS PTY LIMITED (AU) | 2024-01-09 | — | — | US | disclosed |
| US-11858999-B2 | IL-17 receptor A antigen binding proteins | AMGEN K-A, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230190782-A1 | NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF | ASCLETIS BIOSCIENCE CO., LTD. (CN) | 2023-06-22 | — | — | US | disclosed |
| EP-4168092-A1 | BALLOON CATHETER WITH PRECISION DRUG-ELUTING CAPABILITY | C. R. Bard, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| US-20230124150-A1 | COMPLEMENT FACTOR Bb ANTIBODIES | ALLERGAN, INC. | 2023-04-20 | — | — | US | disclosed |
| US-20220376763-A1 | WIRELESS COMMUNICATION METHOD, DEVICE AND COMPUTER READABLE STORAGE MEDIUM THEREOF | ZTE CORPORATION (CN) | 2022-11-24 | — | — | US | disclosed |
| CN-114716544-A | Complement component C5 antibody | 阿勒根公司 | 2022-07-08 | — | — | CN | disclosed |
| EP-4008726-A1 | COMPLEMENT COMPONENT C5 ANTIBODIES | ALLERGAN, INC. (US) | 2022-06-08 | — | — | EP | disclosed |
| CN-114502172-A | Nucleoside prodrugs and related uses thereof | 爱默蕾大学 | 2022-05-13 | — | — | CN | disclosed |
| US-20220088119-A1 | THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF DRY EYE DISEASE | SCHEPENS EYE RESEARCH INSTITUTE | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220088119-A1 | THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF DRY EYE DISEASE | CRYAB, CRYAA, FUCA2 | PTGS1 257/4885ABCC4 2455/4885PTGS2 313/4885 |
| US-20240189337-A1 | NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF | TYMP, NUDT1, PNP | PTGS1 1951/4885ABCC4 797/4885PTGS2 2545/4885 |
| US-20230190782-A1 | NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF | TYMP, NUDT1, PNP | PTGS1 1951/4885ABCC4 797/4885PTGS2 2545/4885 |
| US-11858999-B2 | IL-17 receptor A antigen binding proteins | IL17A, IL23R, IL15RA | PTGS1 3044/4885ABCC4 4121/4885PTGS2 3854/4885 |
| US-20250161402-A1 | THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF DRY EYE DISEASE | CRYAB, CRYAA, FUCA2 | PTGS1 257/4885ABCC4 2455/4885PTGS2 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.